Neurobiology of cognitive disorders

Current Opinion in Psychiatry

Volumn 22, Issue 6, 2009, Pages 546-551

  Kurz, Alexander ^a,b   Perneczky, Robert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Department of Psychiatry and Psychotherapy   (Germany)

Author keywords

Cognitive disorder; Molecular; Neurodegeneration; Oligomers; Protein processing

Indexed keywords

ALPHA SECRETASE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BAPINEUZUMAB; BETA SECRETASE INHIBITOR; BETA SYNUCLEIN; CYCLIN DEPENDENT KINASE 5; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; LITHIUM; METHYLENE BLUE; SEROTONIN 4 AGONIST; TAR DNA BINDING PROTEIN; TARENFLURBIL; TAU PROTEIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; COGNITIVE DEFECT; DRUG TARGETING; HUMAN; MENINGOENCEPHALITIS; NERVE DEGENERATION; NEUROBIOLOGY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SYNAPTIC TRANSMISSION;

AGED; ALPHA-SYNUCLEIN; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; COGNITION DISORDERS; DNA-BINDING PROTEINS; HUMANS; MICE; NEUROBIOLOGY; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; TAU PROTEINS;

EID: 70350139130     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328330588b     Document Type: Review

References (55)

1. Schmahmann JD, Smith EE, Eichler FS, Filley CM. Cerebral white matter. Neuroanatomy, clinical neurology, and neurobehavioral correlates. Ann NY Acad Sci 2008; 1142:266-309.
2. MacLullich AMJ, Ferguson KJ, Miller T, et al. Unravelling the pathophysiology of delirium: a focus on the roles of aberrant stress responses. J Psychosom Res 2008; 65:229-238.
3. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 2009. doi: 10.1007/s00401-009-0536-x.
4. Spires-Jones TL, Stoothoff WH, de-Calignon A, et al. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci 2009; 32:150-159.
5. Castellani RJ, Lee HG, Zhu X, et al. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol 2006; 111:503-509.
6. Weller RO, Boche D, Nicoll JAR. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol 2009; 118:87-102.
7. Minati L, Edginton T, Bruzzone MG, Giaccone G. Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimer's Dis Other Demen 2009; 24:95-121.
8. Meyer-Luehmann M, Spires-Jones TL, Prada C, et al. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008; 451:720-724.
9. Lacor PN. Advances on the understanding of the origins of synaptic pathology in AD. Curr Genomics 2007; 8:486-508.
10. Shughrue PJ, Acton PJ, Breese RS, et al. Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. Neurobiol Aging 2008. doi:10.1016/j.neurobiolaging.2008.04.003.
11. Georganopoulou DG, Chang L, Nam JM, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. PNAS 2007; 102:2273-2276.
12. Lacor PN, Buniel MC, Furlow PW, et al. A beta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007; 27:796-807.
13. Shankar GM, Mahta TH, Garcia-Munoz A, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brain impair synaptic plasticity and memory. Nat Med 2008; 14:837-842.
14. Lord A, Englund H, S̈derberg L, et al. Amyloid-beta protofibril levels correlate with spatial learning in Arctic Alzheimer's disease transgenic mice. FEBS J 2009; 276:995-1006.
15. De Felice FG, Vieria MNN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of A beta oligomers. PNAS 2009; 106:1971-1976.
16. Zhao WQ, De Felice FG, Fernandez S, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2008; 22:246-260.
17. Zhao WQ, Lacor PN, Chen H, et al. Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric A beta. J Biol Chem 2009. doi: 10.1074/jbc.M109.011015.
18. Feulner TM, Laws SM, Friedrich P, et al. Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry 2009. doi:10.1038/mp.2008.141.
19. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splicesite mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393:702-705.
20. Laws SM, Friedrich P, Diehl-Schmid J, et al. Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease. Mol Psychiatry 2007; 12:510-517.
21. Wolfe MS. Tau mutations in neurodegenerative diseases. J Biol Chem 2009; 284:6021-6025.
22. Sergeant N, Bretteville A, Hamdane M, et al. Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics 2008; 5:207-224.
23. Reynolds CH, Garwood CJ, Wray S, et al. Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases. J Biol Chem 2008; 283:18177-18186.
24. Hooper C, Killick R, Lovestone S. The GSK-3 hypothesis of Alzheimer's disease. J Neurochem 2008; 104:1433-1439.
25. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001; 2:492-501.
26. Bisaglia M, Schievano E, Caporale A, et al. The 11-mer repeats of human alpha-synuclein in vesicle interactions and lipid composition discrimination: a cooperative role. Biopolymers 2006; 84:310-316.
27. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55:164-173.
28. Ibanez P, Bonnet AM, Debarges B, et al. Causal relation between alphasynuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364:1169-1171.
29. Kruger R, Vieira-Saecker AM, Kuhn W, et al. Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/ apolipoprotein E genotype. Ann Neurol 1999; 45:611-617.
30. Cookson MR, van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 2008; 209:5-11.
31. Larsen KE, Schmitz Y, Troyer MD, et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 2006; 26:11915-11922.
32. Elkon H, Don J, Melamed E, et al. Mutant and wild-type alpha-synuclein interact with mitochondrial cytochrome C oxidase. J Mol Neurosci 2002; 18:229-238.
33. Jiang H,Wu YC, Nakamura M, et al. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death. Neurobiol Aging 2007; 28:1709-1717.
34. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314:130-133.
35. Schumacher A, Friedrich P, Diehl-Schmid J, et al. No association of TDP-43 with sporadic frontotemporal dementia. Neurobiol Aging 2009; 30:157-159.
36. Cairns NJ, Neumann M, Bigio EH, et al. TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 2007; 171:227-240. (Pubitemid 47342406)
37. Zhang YJ, Xu YF, Cook C, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A 2009; 106:7607-7612.
38. Steinacker P, Hendrich C, Sperfeld AD, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol 2008; 65:1481-1487.
39. Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. BMC Medicine 2009; 7:7.
40. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of A beta 42 immunisation in Alzheimer's disease: follow-up of a randomised, placebocontrolled phase I trial. Lancet 2008; 372:216-223.
41. Postina R. A closer look at alpha-secretase. Curr Alzheimer Res 2008; 5:179-186.
42. Ghosh AK, Gemma S, Tang J. Beta-secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics 2008; 5:399-408.
43. Wolfe MS. Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics 2008; 5:391-398.
44. Deshpande A, Kawai H, Matherate R, et al. A role for synaptic zinc in activitydependent Abeta oligomer formation and accumulation at excitatory synapses. J Neurosci 2009; 29:4004-4015.
45. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 2009; 15:112-119.
46. Martin L, Magnaudeix A, Esclaire F, et al. Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A. Brain Res 2009; 1252:66-75.
47. Caccamo A, Oddo S, Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 2007; 170:1669-1675.
48. Bulic B, Pickhardt M, Schmidt B, et al. Development of tau aggregation inhibitors for Alzheimer's disease. Angew Chem Int Ed Engl 2009; 48:1740-1752.
49. Hattori M, Sugino E, Minoura K, et al. Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain. Biochem Biophys Res Commun 2008; 374:158-163.
50. Wischik C, Bentham D, Wischik DJ, Seng K. Tau aggregation inhibitor (TAI) therapy with rember arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimer's Dementia 4 (4): T167. doi:10.1016/j.jalz.2008.05.438.
51. Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 2008; 15:157-168.
52. Emadi S, Liu R, Yuan B, et al. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 2004; 43:2871-2878.
53. Masliah E, Rockenstein E, Adame A, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005; 46:857-868.
54. Hashimoto M, Rockenstein E, Mante M, et al. An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther 2004; 11:1713-1723.
55. Rockenstein E, Hansen LA, Mallory M, et al. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res 2001; 914:48-56.